<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644017</url>
  </required_header>
  <id_info>
    <org_study_id>CVO-P1-18-01</org_study_id>
    <nct_id>NCT03644017</nct_id>
  </id_info>
  <brief_title>The Merit WRAPSODY™ Endovascular Stent Graft</brief_title>
  <official_title>Prospective Investigation of The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Venous Outflow Circuit Obstruction In Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merit Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study, designed to evaluate the safety and effectiveness of the WRAPSODY&#xD;
      Stent Graft for the treatment of venous outflow circuit obstructions in the veins of the arm&#xD;
      or thoracic central veins of subjects who receive chronic dialysis treatment for end stage&#xD;
      renal disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a screening period in which subject eligibility will be determined.&#xD;
      Approximately 50 subjects meeting the study entry criteria will be enrolled. Placement of the&#xD;
      WRAPSODY stent graft will follow the procedure. Post study procedure subjects will have&#xD;
      planned follow-up visits at 30 days, 3, 6 and 12months, and additional visits as referred by&#xD;
      the subject's dialysis facility.&#xD;
&#xD;
      The primary study safety endpoint will be the proportion of subjects without any localized or&#xD;
      systemic safety events through 30 days that affect the access or venous outflow circuit and&#xD;
      resulted in surgery, hospitalization, or death. Subjects will continue to be followed up to&#xD;
      12 months for supplementary information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2019</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm treated with investigational device WRAPSODY Stent Graft</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Without Any Localized or Systemic Safety Events Through 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>The total number of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Lesion Primary Patency</measure>
    <time_frame>30 days</time_frame>
    <description>The total number of subjects with Target Lesion Primary Patency at 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Primary Patency</measure>
    <time_frame>3 months</time_frame>
    <description>The total number of subjects with Target Lesion Primary Patency at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Primary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>The total number of subjects with Target Lesion Primary Patency at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>The total number of subjects with Target Lesion Primary Patency at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Target Lesion Primary Patency</measure>
    <time_frame>30 days</time_frame>
    <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Target Lesion Primary Patency</measure>
    <time_frame>3 months</time_frame>
    <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Target Lesion Primary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Target Lesion Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Primary Patency</measure>
    <time_frame>30 days</time_frame>
    <description>The total number of subjects with Access Circuit Primary Patency at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Primary Patency</measure>
    <time_frame>3 months</time_frame>
    <description>The total number of subjects with Access Circuit Primary Patency at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Primary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>The total number of subjects with Access Circuit Primary Patency at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Access Circuit Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>The total number of subjects with Access Circuit Primary Patency at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Access Circuit Primary Patency</measure>
    <time_frame>30 days</time_frame>
    <description>The total number of subjects with Assisted Access Circuit Primary Patency at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Access Circuit Primary Patency</measure>
    <time_frame>3 months</time_frame>
    <description>The total number of subjects with Assisted Access Circuit Primary Patency at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Access Circuit Primary Patency</measure>
    <time_frame>6 months</time_frame>
    <description>The total number of subjects with Assisted Access Circuit Primary Patency at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assisted Access Circuit Primary Patency</measure>
    <time_frame>12 months</time_frame>
    <description>The total number of subjects with Assisted Access Circuit Primary Patency at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 days</time_frame>
    <description>The resumption of successful dialysis through existing access for at least one session following the initial study procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anatomic Success</measure>
    <time_frame>Immediately following the study procedure</time_frame>
    <description>Less than 30% residual stenosis immediately following the study procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>30 days</time_frame>
    <description>The achievement of both clinical and anatomic success</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Stent Graft Integrity (Subset of Subjects With Thoracic Central Venous Target Lesions Only)</measure>
    <time_frame>12 months</time_frame>
    <description>Measured as freedom from stent graft fracture, defined as clear interruption of a stent strut observed in a minimum of two projections taken during the 12 month visit or after determined by DMC/CEC examination of X-Ray images.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Venous Stenosis</condition>
  <condition>Venous Occlusion</condition>
  <arm_group>
    <arm_group_label>WRAPSODY Stent Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WRAPSODY Stent Graft Placement</intervention_name>
    <description>The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
    <arm_group_label>WRAPSODY Stent Graft</arm_group_label>
    <other_name>Stent Graft</other_name>
    <other_name>Covered Stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has signed informed consent&#xD;
&#xD;
          2. Subject is ≥ 21 years of age&#xD;
&#xD;
          3. Subject is undergoing chronic hemodialysis or other forms of renal replacement therapy&#xD;
             including transplantation and has one of the following being used: a. AV graft placed&#xD;
             in the arm ≥30 days prior OR b. Mature fistula in the arm with at least one successful&#xD;
             dialysis session completed&#xD;
&#xD;
          4. Angiographic evidence of stenosis&#xD;
&#xD;
          5. The target lesion has ≥ 50% stenosis&#xD;
&#xD;
          6. Subject has clinical or hemodynamic evidence of a venous outflow stenosis or&#xD;
             obstruction&#xD;
&#xD;
          7. Full expansion of an appropriately sized standard angioplasty balloon has been&#xD;
             achieved during primary angioplasty at the target lesion prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has undergone an intervention (surgical or percutaneous) of the AVF/AVG &lt;30&#xD;
             days from the date of the initial study procedure&#xD;
&#xD;
          2. Subject has had a previous stent or stent graft placed in the venous outflow circuit&#xD;
             ≤30 days from the date of the initial study procedure&#xD;
&#xD;
          3. Active hemodialysis access is not in the arm&#xD;
&#xD;
          4. A pseudoaneurysm is present within the target lesion&#xD;
&#xD;
          5. Target lesion is in SVC, IJV, under the clavicle, across the elbow, in the needling&#xD;
             segment of AVF or AVG anastomosis, located within a stent&#xD;
&#xD;
          6. Lesions, other than the target lesion, in the venous outflow circuit with &gt;30%&#xD;
             stenosis&#xD;
&#xD;
          7. Known or suspected infection of the hemodialysis access site and/or septicemia&#xD;
&#xD;
          8. Permanent pacemaker or automated implantable cardioverter defibrillator (AICD) on the&#xD;
             side with the target lesion&#xD;
&#xD;
          9. Current central venous catheter for dialysis access&#xD;
&#xD;
         10. Uncorrectable coagulation disorders&#xD;
&#xD;
         11. Hypersensitivity to nickel titanium alloy&#xD;
&#xD;
         12. The subject is enrolled in another investigational study&#xD;
&#xD;
         13. The subject is unable or unwilling to comply with the protocol requirements&#xD;
&#xD;
         14. Life expectancy is ≤ 12 months&#xD;
&#xD;
         15. Subject cannot receive heparin or equivalent anticoagulant&#xD;
&#xD;
         16. Allergy to radiographic contrast material which cannot be adequately premedicated&#xD;
&#xD;
         17. Subject is pregnant, breastfeeding, or pre-menopausal and intending to become pregnant&#xD;
&#xD;
         18. Subject's access is anticipated to be abandoned within 3 months&#xD;
&#xD;
         19. Subject has a thoracic central vein obstruction that would lead to stent graft&#xD;
             placement across the internal jugular vein&#xD;
&#xD;
         20. Subject's hemodialysis access is thrombosed&#xD;
&#xD;
         21. Active malignancy other than non-melanomatous skin cancer&#xD;
&#xD;
         22. Any other condition deemed exclusionary in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Gilbert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>G. Gennimatas General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2021</results_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>Venous Stenosis</keyword>
  <keyword>Venous Occlusion</keyword>
  <keyword>Stent Graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03644017/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>WRAPSODY Stent Graft</title>
          <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Access Abandonment</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Kidney Transplant</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>WRAPSODY Stent Graft</title>
          <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Without Any Localized or Systemic Safety Events Through 30 Days</title>
        <description>The total number of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Without Any Localized or Systemic Safety Events Through 30 Days</title>
          <description>The total number of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Primary Patency</title>
        <description>The total number of subjects with Target Lesion Primary Patency at 30 days</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Primary Patency</title>
          <description>The total number of subjects with Target Lesion Primary Patency at 30 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Primary Patency</title>
        <description>The total number of subjects with Target Lesion Primary Patency at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Primary Patency</title>
          <description>The total number of subjects with Target Lesion Primary Patency at 3 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Primary Patency</title>
        <description>The total number of subjects with Target Lesion Primary Patency at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Primary Patency</title>
          <description>The total number of subjects with Target Lesion Primary Patency at 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Primary Patency</title>
        <description>The total number of subjects with Target Lesion Primary Patency at 12 months</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Target Lesion Primary Patency</title>
        <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 30 days</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Target Lesion Primary Patency</title>
          <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 30 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Target Lesion Primary Patency</title>
        <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Target Lesion Primary Patency</title>
          <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 3 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Target Lesion Primary Patency</title>
        <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Target Lesion Primary Patency</title>
          <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Target Lesion Primary Patency</title>
        <description>The total number of subjects with Assisted Primary Patency of the Target Lesion at 12 months</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Access Circuit Primary Patency</title>
        <description>The total number of subjects with Access Circuit Primary Patency at 30 days</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Access Circuit Primary Patency</title>
          <description>The total number of subjects with Access Circuit Primary Patency at 30 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Access Circuit Primary Patency</title>
        <description>The total number of subjects with Access Circuit Primary Patency at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Access Circuit Primary Patency</title>
          <description>The total number of subjects with Access Circuit Primary Patency at 3 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Access Circuit Primary Patency</title>
        <description>The total number of subjects with Access Circuit Primary Patency at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Access Circuit Primary Patency</title>
          <description>The total number of subjects with Access Circuit Primary Patency at 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Access Circuit Primary Patency</title>
        <description>The total number of subjects with Access Circuit Primary Patency at 12 months</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Access Circuit Primary Patency</title>
        <description>The total number of subjects with Assisted Access Circuit Primary Patency at 30 days</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Access Circuit Primary Patency</title>
          <description>The total number of subjects with Assisted Access Circuit Primary Patency at 30 days</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Access Circuit Primary Patency</title>
        <description>The total number of subjects with Assisted Access Circuit Primary Patency at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Access Circuit Primary Patency</title>
          <description>The total number of subjects with Assisted Access Circuit Primary Patency at 3 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Access Circuit Primary Patency</title>
        <description>The total number of subjects with Assisted Access Circuit Primary Patency at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Assisted Access Circuit Primary Patency</title>
          <description>The total number of subjects with Assisted Access Circuit Primary Patency at 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assisted Access Circuit Primary Patency</title>
        <description>The total number of subjects with Assisted Access Circuit Primary Patency at 12 months</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>The resumption of successful dialysis through existing access for at least one session following the initial study procedure</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>The resumption of successful dialysis through existing access for at least one session following the initial study procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anatomic Success</title>
        <description>Less than 30% residual stenosis immediately following the study procedure</description>
        <time_frame>Immediately following the study procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Anatomic Success</title>
          <description>Less than 30% residual stenosis immediately following the study procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>The achievement of both clinical and anatomic success</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>WRAPSODY Stent Graft</title>
            <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>The achievement of both clinical and anatomic success</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Stent Graft Integrity (Subset of Subjects With Thoracic Central Venous Target Lesions Only)</title>
        <description>Measured as freedom from stent graft fracture, defined as clear interruption of a stent strut observed in a minimum of two projections taken during the 12 month visit or after determined by DMC/CEC examination of X-Ray images.</description>
        <time_frame>12 months</time_frame>
        <posting_date>01/2022</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>WRAPSODY Stent Graft</title>
          <description>All subjects will receive treatment via WRAPSODY Stent Graft Placement.&#xD;
WRAPSODY Stent Graft Placement: The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Arteriovenous graft thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The endpoint final analysis results to 6 months have been posted. Full final results for other study timepoints will be added after the analysis has been completed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Casey Holland, Senior Director Clinical Operations</name_or_title>
      <organization>Merit Medical Systems, Inc.</organization>
      <phone>+1 (617) 842-0251</phone>
      <email>casey.holland@merit.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

